Key facts
- It has raised $22.9M; the latest was Early Stage VC ($10.1M) in Aug 2025.
- Notable investors include IBK Changgong, Korea Development Bank, Enlight Ventures, Korea Technology Finance, HG Initiative — 26 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 26 names
- ·Watchlist + deal alerts for SCBio (Drug Discovery)
- ·The full record, as it builds
Funding rounds
No funding rounds for SCBio (Drug Discovery) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SCBio (Drug Discovery)
Operator of a pharmaceutical company intended to focus on making drugs to improve well-being. The company's services include discovering and developing novel therapeutics, leading innovations for future medicine, offering timely services for product selection, and launching strategies, and supply mitigation, providing patients with access to medicines with specialized technologies in immuno-oncology.
- Sector
- Healthcare
- HQ
- Daejeon, South Korea
- Founded
- 2021
- Employees
- 32
- Website
- sc-bio.co.kr/
- Ownership
- Privately Held (backing)
SCBio (Drug Discovery) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SCBio (Drug Discovery) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SCBio (Drug Discovery) in its N-PORT filings yet. We sweep new filings monthly.